- Home
- CHI vs BLFS Comparison
CHI vs BLFS Comparison
Compare CHI & BLFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CHI | BLFS |
|---|---|---|
| Founded | 2002 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 930.8M | 923.5M |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | CHI | BLFS |
|---|---|---|
| Price | $11.92 | $22.29 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | 214.4K | ★ 310.1K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 9.90% | N/A |
| EPS Growth | N/A | ★ 77.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $96,214,000.00 |
| Revenue This Year | N/A | $19.73 |
| Revenue Next Year | N/A | $17.82 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.97 |
| 52 Week Low | $9.42 | $17.86 |
| 52 Week High | $12.13 | $29.57 |
Technical Indicators
Market Signals| Indicator | CHI | BLFS |
|---|---|---|
| Relative Strength Index (RSI) | 66.91 | 65.09 |
| Support Level | $10.84 | $21.35 |
| Resistance Level | $12.13 | $23.15 |
| Average True Range (ATR) | 0.26 | 0.85 |
| MACD | 0.08 | 0.37 |
| Stochastic Oscillator | 87.88 | 93.99 |
Price Performance
Historical ComparisonAbout CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.